The optimization of recombinant antibody production from Chinese hamster ovary (CHO) cells remains a paramount challenge for the biopharmaceutical industry. Various strategies are employed to antibody titer, comprising process parameter optimization, cell line development, and the use of perfusion systems. Fine-tuning growth parameters plays a cr